BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Asthmatx, Inc. Pivotal Trial Manuscript for Bronchial Thermoplasty Published in the American Journal of Respiratory and Critical Care Medicine


1/12/2010 8:38:06 AM

SUNNYVALE, Calif., Jan. 12 /PRNewswire/ -- Asthmatx Inc., developer of bronchial thermoplasty with the Alair(R) System, announced today the publication of positive results from its pivotal study, the Asthma Intervention Research 2 (AIR2) Trial, in the American Journal of Respiratory and Critical Care Medicine (AJRCCM). The publication, entitled "Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial," demonstrated statistically significant reductions in asthma attacks (severe exacerbations) and emergency room visits for respiratory symptoms, as well as improvements in quality of life in adults with severe asthma who underwent bronchial thermoplasty with the Alair System.

"Bronchial thermoplasty decreases severe exacerbations and ER visits for respiratory symptoms and improves quality of life in patients with severe asthma," said Mario Castro, MD, Professor of Medicine and Pediatrics at the Washington University School of Medicine, a principal investigator in the AIR2 Trial and the lead author of the paper. "Bronchial thermoplasty with the Alair System offers clinicians a novel adjunctive therapy option, beyond the current use of inhaled corticosteroids and long acting beta agonists, to provide improvements in overall asthma control."

The AIR2 Trial was designed to evaluate the safety and effectiveness of bronchial thermoplasty in adult patients with severe asthma who remain symptomatic, despite treatment with standard of care medications (high dose inhaled corticosteroids and long-acting beta agonists). The study was a randomized, double-blind, sham-controlled trial that enrolled 297 patients at 30 sites in six countries. The primary effectiveness endpoint was the change from baseline in Asthma Quality of Life Questionnaire (AQLQ) score. Safety was assessed by comparing the short and long-term (out to one year) safety profiles for both the active and sham treatment groups.

In addition to an improvement in quality of life as measured by an increase in average Asthma Quality of Life Questionnaire (AQLQ) score at 6, 9, and 12 months in the active compared to the sham group, there were also improvements in overall asthma control as demonstrated by the following key statistically significant clinical findings of the AIR2 Trial during long-term follow-up:

In the period immediately following bronchial thermoplasty, there was an expected increase and worsening of respiratory-related symptoms, which were of the type expected following bronchoscopy in patients with asthma. These events typically occurred within a day of the procedure and resolved on average within seven days with standard care. In the long term after treatment, fewer bronchial thermoplasty treated patients reported respiratory adverse events. The report in AJRCCM concluded that the increased risk of adverse events in the short-term following the procedure is outweighed by the benefit of bronchial thermoplasty that persists for at least one year.

In October of 2009, the Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee to the U.S. Food and Drug Administration (FDA) voted to recommend that the Alair(R) System be found approvable with conditions based on the results of this and other studies. The application for FDA approval of the Alair System is presently under review by FDA.

About Bronchial Thermoplasty Delivered by the Alair System

Bronchial thermoplasty is a bronchoscopic procedure for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long acting beta agonists. Bronchial thermoplasty is performed through the working channel of a standard flexible bronchoscope that is introduced through a patient's nose or mouth, and into their lungs. The tip of the small diameter Alair(R) catheter is expanded to contact the walls of targeted airways. Controlled thermal energy is then delivered to the airway walls to reduce the presence of airway smooth muscle that narrows the airways in patients with asthma. The minimally invasive procedure, like many other flexible endoscopy procedures, is done under moderate sedation, and the patient returns home the same day. For more information on bronchial thermoplasty visit www.bronchialthermoplasty.com.

CAUTION: Alair System is an Investigational Device. It is limited by United States law to investigational use. To be used by Qualified Investigators only.

Alair, Asthmatx and the Asthmatx logo are registered trademarks of Asthmatx, Inc.

About Asthmatx

Asthmatx is developing catheter-based medical devices for the treatment of asthma. Asthmatx has developed the Alair System to perform an investigational outpatient procedure called bronchial thermoplasty. The Alair System has received a CE Mark for use in the European Union. For more information on Asthmatx visit www.asthmatx.com.

CONTACT: Scott Shadiow of WCG, +1-415-946-1093, sshadiow@wcgworld.com, for
Asthmatx Inc.

Web site: http://www.asthmatx.com//



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES